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Abstract
Background: The study aimed at evaluating the prevalence of thyroid function abnormalities in
patients with alopecia areata (AA) and its association with other autoimmune diseases and various
autoimmune antibodies.
Method: We retrospectively analyzed medical records of 123 patients with AA. The main site of
involvement, pattern, and extent of alopecia as well as presence of the similar disease in first-degree
family members and serologic status of patients were recorded.
Results: Participating in the study were 57 males and 66 females (6 to 59 years old). In the majority
of patients (69.9%) the disease was manifested in the first two decades of life. Patients with family
members having alopecia were recorded in 24.4%. Thyroid function abnormalities were found in
8.9% of patients. Positive autoimmune antibodies were associated with AA in 51.4% of patients with
no significant association between the severity and duration of disease and presence of these
antibodies.
Conclusion: The incidence of positive auto-immune antibodies in Iranian patients is higher than
previous reports. Concerning the female:male ratio, thyroid function tests and the prevalence of
alopecia in first-degree relatives, our results are compatible with previous data obtained from
different ethnic populations. Previous reports documented that a greater severity and longer
duration of AA were seen in the early onset forms; however our result are relatively different
which could be explained by differences in genetic factors.
Background
Alopecia areata (AA) is a non-scarring hair disorder, the
etiology of which is minimally understood. Since human
hair has an important communicational role and also
because it is predominantly a disease of the youth, this
disorder is able to cause significant psychological distress.
Therefore, it would be extremely grateful to find appropri-
ate measures to overcome this relatively stressful disorder.
This aim is only when achieved that the main underlying
causes of the disorder have been discovered.
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Although many different pathogenic causes have been
proposed, the determination of the exact underlying etiol-
ogy of AA is extremely problematic. In fact, these difficul-
ties are in part due to variable extent of the disease and the
heterogonous and poorly defined nature of the patients
studied. Of the numerous pathogenic processes which
have been proposed as the underlying pathogenic causes
of the AA, immunological, environmental, psychological,
and genetic factors [1,2] are the most powerful explana-
tions, but the relative significance of each is not com-
pletely known. For example, the genetic basis is explained
by a higher familial occurrence, with a positive family his-
tory in 10–42% of patients in different populations [3].
There are also lots of data concerning the contribution of
autoimmune processes in the pathogenesis of AA and in
fact these evidences are more convincing [4]. The associa-
tion of AA with other auto-immune processes, such as
auto-immune thyroiditis and diabetes mellitus has been
widely reported and has been considered as a potent indi-
cator of the contribution of auto-immunity in the patho-
genesis of the AA [5]. Although all these evidences suggest
that the hair can be considered a target organ for autoim-
mune processes, presence of remarkable data concerning
the contribution of psychological, environmental and
genetic predisposing factors make it difficult to determine
the exact cause of the disorder.
Also there is a lack of agreement on the overall prevalence
of thyroid disease and thyroid function abnormalities in
alopecia areata [6] and the prevalence of thyroid disease
in patients with alopecia areata in previous reports varies
from 8 to 28% [7]. Unfortunately, no study is available
from the Iranian subcontinent.
The aim of our study was to evaluate the frequency of thy-
roid function abnormalities, antithyroid auto-antibodies
and few other well-known autoimmune antibodies [anti-
nuclear antibody (ANA), anti-smooth muscle antibody
(SMA), anti-parietal cell antibody (PCA), anti-thyroglob-
ulin antibodies (anti-Tg)] in Iranian patients affected by
AA. Moreover, we intended to assess the prevalence of AA
between the first degree relatives of our patients.
Methods
The study was carried out at the dermatology department
(Tehran University of medical sciences) between February
2002 and July 2004. The data were collected retrospec-
tively and systematically in a pre-established question-
naire. AA was diagnosed according to the definition of
Olsen et al. [8]. The extent of hair loss was classified as <
50% (S1–S2) involvement, 50–99% (S3–S4) involve-
ment, alopecia totalis (AT), and alopecia universalis (AU)
at the time of presentation. All patients with AA were
entered in the analysis. During the data collection, the
main site of involvement, pattern, and extent of alopecia
were recorded. Also a physical examination directed
toward signs of other systemic or autoimmune diseases
and the history of AA in first degree relatives were stated.
The data of serologic status [ANA, SMA, PCA, anti-Tg, and
routine thyroid function tests (including Free T3, Free T4,
and TSH)] were collected from the medical records of
patients. The serum level of SMA, ANA and PCA (positive
titre ≥1:80) were measured by indirect immunofluores-
cence (IIF) according to the standard protocols (Iason
Labormedizin, Graz, Austria). Free T3 (FT3, normal range:
3–7.5 pmol/l), TSH (normal range: 0.5–3.5 mU/l), and
anti-Tg (positive titer > 1:100) were measured by the
chemiluminesence fluorescence method (Bayer Diagnos-
tics, Leverkusen, Germany).
Statistical analysis
The associations were analyzed by chi-square, Fischer
bicaudal exact test and T test. A probability of less than
0.05 was considered significant. SPSS for Windows
(Release 11.5.0) was used for statistical analysis.
Results
A total of 123 patients with Alopecia disorders, including
57 (46.3%) males and 66 (53.7%) females were entered
in our analysis (female: male ratio = 1.15:1). Of these, 57
patients (46.3%) had AT, 12 patients (9.8%) AU and 54
patients (43.9%) patchy alopecias. The age of patients at
the onset of the disease had a wide range from 6 to 59
years (24.05 ± 9.98, mean ± SD). The peak age at the onset
of the disease for either sex was 15 to 25 years, constitut-
ing 45.5% of the whole population of the patients. 86
patients (69.9%) experienced their first episode of AA
before 20 years old. Although involving with the severe
forms of the disease was seen more frequently in those
patients who had early onset alopecias, but considering
the severity and the duration of the disease no significant
difference was found between the different age groups of
patients.
Involvement of the family members with AA was found in
30 of 123 patients (24.4%). Abnormalities of thyroid
function were detected in 11 (8.9%) patients included 7
(63.6%) male and 4 (36.4%) female. Of these, 3 patients
(2.4%) had T3, 4 patients (3.2%) T4 and 10 patients
(8.2%) TSH abnormalities. Presence of auto-immune
antibodies (ANA, SMA, Anti-Tg and PCA) was established
in 62 patients (51.4%). Of the 123 patients investigated
for Anti-Tg, 36 patients (29.3%) had positive titer, includ-
ing 27 men (22%) and 9 women (7.3%). Of these, posi-
tive titers were detected in 16 patients with the patchy
form of the disease (13%) and 20 patients with AU
(16.3%) (Table 1). Although positive titer was observed in
22 patients (21.1%) affected with AA before 20 years, but
there was no statistically significant difference betweenBMC Dermatology 2005, 5:11 http://www.biomedcentral.com/1471-5945/5/11
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the positivity of Anti-Tg test and the age of patients at the
onset of the disease (Table 2). A higher proportion of
patients (18.2%) with a longer duration of disease (>5
years) compared with patients with length of disease less
than 1 year (1.9%) have positive anti-Tg titer, but differ-
ences did not attain statistical significance. Of 19 (15.5%)
patients with positive PCA titer, 13 patients (10.8%) pre-
sented with AU and 6 (4.9%) with patchy forms but there
was no significant association between the severity of dis-
ease and positivity of PCA. Of 19 patients who have posi-
tive PCA titer, 11 patients (6.9%) were afflicted longer
than 5 years. There were also no significant differences
between duration of disease and presenting positive anti-
parietal antibody. 5 (4.8%) of 123 patients presented with
SMA, all of them were between 15 to 25 years and the
onset of disease was before 10 years old (Table 3). Two
(1.8%) women in the patchy form group were seroposi-
tive for ANA. Both were involved before 20 years old and
afflicted by disease for more than 5 years (Table 4).
Discussion
Alopecia is an ancient disease and was known to Egyp-
tians even before Christ [9]. Despite its long history, our
knowledge is actually limited. Generally, significant
differences have been identified in the profile of the dis-
ease among different societies [10].
Previous studies have revealed that AA affects both sexes
equally [11,12] with females slightly more predominan-
ated [3,13,14]; Similar findings have been obtained in our
study with slight predominance of the females
(female:male ratio = 1.15:1).
AA may begin as early as the fourth month of the life [15]
or as late as in the late seventies [12]. Our findings were
not very different and the youngest patient in our group of
patients was a 6 years and the oldest was 59. The preva-
lence of AA presenting before 20 years was reported previ-
ously to be between 27–44% [16], whereas the result in
the current study was interestingly higher (69.9%). This
disparity is difficult to explain and could be due to racial
and genetic factors.
AA has been considered as an auto-immune disease, due
to an aberrant T cell response against hair follicle self-anti-
gens [17]. This auto-immune etiology has been also pro-
posed on the basis of its association with various auto-
immune diseases, the presence of auto-antibodies and
various underlying immunologic abnormalities in the
affected sites of these patients [10].
One of the main associations is with thyroid abnormali-
ties [5]. The incidence of thyroid disease has varied from
8 to 28% in patients with AA [16]. Milgraum et al. also





Patchy 16 13 14 11.4
AT 0 0 57 46.3
AU 20 16.3 16 13
Total 36 29.3 87 70.7





5–14 5 4.1 13 10.5
15–24 20 16.2 33 26.9
25–34 64 . 9 2 11 7
35–44 5 4.1 11 9
>44 009 7 . 3
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found an apparent association between thyroid disease
and AA [4]. Subsequently Lewinski et al confirmed the fre-
quent co-existence of AA and thyroid abnormalities [18].
Conversely, in 1994 Puavilai et al. estimated that the prev-
alence of thyroid disease is relatively low (7.2%) and they
were not statistically different from patients with AA and
control group [7]. In our study, 8.9% of patients had
abnormal thyroid function tests, which relatively correlate
with previous reports. We should note that the prevalence
of thyroid disease in the Iranian normal population is
2.97% [19], hence our patients show higher incidence of
thyroid diseases in comparison with normal individuals.
Many reports found significant associations between alo-
pecia areata and autoimmune endocrinopathies [5], but
other studies do not confirm this [20]. In a report of large
number of cases from North America [3], auto-immune
diseases were closely associated with AA in 17.1% of
patients. However, in the study of Vinod et al in 1996, the
corresponding features were much lower (5%) [16].
In previous studies SMA and PCA were found in 34.6%
and 42.3% of the patients, respectively, followed by
antithyroglobulin antibody in 2.8% [21]. In our study,
these auto-immune antibodies were associated with AA in
15.5% and 4.8% of patients, which are much lower than
the previous report of Kumar et al. These authors have
themselves also interested in their results and mentioned
that AA in India is associated more often with antismooth
muscle and antiparietal cell antibodies.
Generally the frequency of autoantibodies in Iranian
patients (51.4%) is higher than the other populations
[3,16]. It is next to impossible to offer an adequate expla-
nation of the real causes of these differences and may
partly be attributed to racial and genetic factors.
It is well-known that various kinds of auto-antibodies are
found in each population of healthy individuals. The lim-
itation that forced itself upon our research study was the
fact that because of retrospective nature, we did not posses
any control group in order to compare the results
obtained from the study of antibodies; however, it must
be admitted that a report concerning the rate of antithy-
roglobulin and ANA antibodies in normal Iranian popu-
lation exists [19]. The result of this study has reported the
rate of anti-Tg antibody and ANA, 16.2% and 1.7% of the
normal Iranian population, respectively. We have made a
comparison of the anti-Tg and ANA rate in our patients
with the above result. In our study the prevalence of posi-
tive anti-Tg antibodies in patients was higher than normal
Iranian population (29.8% versus 16.2%), but the fre-
quency of ANA titer is relatively equal in our patients and
normal individuals (1.8% versus 1.7%). On the other
hand, the prevalence of these antibodies in our patients is
Table 3: The frequency of positive anti-smooth muscle antibody among the different age groups.
Anti SM Ab/Age group Positive Negative
n%n%
5–14 00 2 1 1 7
15–24 64 3 8 3 1
25–34 0 0 26 21.1
35–44 00 2 1 1 7
>44 00 1 1 9
Total 5 4.8 118 95.1
Table 4: The frequency of positive ANA among the different age groups.
ANA/Age group Positive Negative
n%n%
5–14 0 0 18 16.2
15–24 1 0.9 49 44.1
25–34 0 0 26 23.4
35–44 0 0 13 11.8
>44 10 . 932 . 7
Total 2 1.8 109 98.2Publish with BioMed Central    and   every 
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not consistent with the previous study of Okamoto et al
[22], in which the prevalence of positive ANA in the
patients afflicted with AA was remarkably higher than our
patients (53% versus 1.8%). Over all, on account of
genetic factors, the prevalence of auto-antibodies is not
similar in the different societies, even in the normal pop-
ulation. For example the positive titer of ANA in the nor-
mal Iranian population is 1.8%, while it was estimated
that in the normal Japanese it is about 15% [22]. This dif-
ference emphasize on the fact that we could not compare
the results of different communities. Unfortunately, we
could not find any information about the value of SMA
and PCA in normal populations.
Family members having AA has been reported in 10 to
20% of patients [12-14]. Our figure of 24.4% is close to
the upper limit of the above reports and this higher prev-
alence of the disease in the first degree relatives of the
patients as compared to the previous reports of the other
communities, emphasizes again on the importance of the
genetic factors in our population. However, it should be
also considered that the patients in the clinic of a Univer-
sity Hospital may have disease more severe than the aver-
age and this may be the reason for the high frequency of a
positive family history. On the other hand, in previous
publications, the highest family history rates have often
been in small series and bias in ascertainment of the cases
is often the reason for this.
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